|
Market Cap (17-May) $41,071,320 (780th) |
Close (30-Jun) $0.081 |
Volume (30-Jun) 2,818,974 |
Shortsold (13-Feb) 21,991 (0.00%) (605th) |
|
52w High $0.063 |
52w Low $0.037 |
P/E - |
EPS -0.01 |
PTX released this announcement to the ASX on 16 March 2023, 9:53. The announcement is marked as price sensitive, and is 7 page(s) in length and 2.08MB in size.
You can view all announcements from PTX and see how they appear on a price chart on the announcements page.
At the date of this announcement, PTX was 0.089% short sold according to ASIC data. It was ranked the 481st most shorted stock on the ASX. It remains ranked 605th as of the latest reported data (13 February 2024).
| Other Recent Announcements from PTX | |
|---|---|
| Application for quotation of securities - PTX | 14 June 2023, 15:38 |
| Two PTX abstracts accepted at prestigious ISCT conference | 16 May 2023, 8:59 |
| Initial Director's Interest Notice | 15 May 2023, 14:31 |
| Continued promising results in PTX-100 TCL trial | 16 March 2023, 9:53 |
| FDA grants broader orphan drug status to PTX100 for TCLs | 9 March 2023, 9:14 |
| Revised Securities Trading Policy | 27 February 2023, 15:22 |
| Appendix 4D and Half Year Financial Report | 24 February 2023, 13:38 |
You must be logged in to post a reply.
Prescient Therapeutics 